Skip to content
Leading Medicine Guide logo

Expert Interviews

An overview of symptoms, treatment and modern surgical procedures

Alexandra_Pfitzmann.jpg

Alexandra Pfitzmann ·

Meningiomas and gliomas are among the most common types of brain tumour – yet they differ significantly in their aetiology, behaviour and therapeutic requirements. Whilst meningiomas often grow slowly and can initially be monitored, gliomas require a particularly precise and modern surgical strategy due to their biological characteristics. The aim is always to detect symptoms early, select the correct therapy and make the treatment as safe and effective as possible.

Prof. Dr. med. Pantelis Stavrinou

At the start of our conversation, Prof. Dr. Stavrinou explains: “Meningiomas are among the most common primary tumours within the skull, and it is particularly important for those affected to know that the vast majority are benign and grow very slowly. Thanks to the widespread use of MRI, many of these tumours are now discovered incidentally, for example during investigations for headaches, migraines or following a traumatic brain injury. The causes are usually unclear, as with many brain tumours, although certain risk factors are known: ionising radiation during childhood, rare genetic disorders and, presumably, hormonal influences, which could explain why meningiomas occur more frequently in women. Crucially, not every meningioma requires treatment. Small, asymptomatic tumours discovered by chance are often simply monitored over a period of years – an approach known as ‘watch-and-wait’. In this approach, the focus is not on the MRI scan but on the patient’s actual condition. Meningiomas do not originate in the brain itself, but grow from the meninges, a thin layer surrounding the brain. A distinction is made between two main groups: convexity meningiomas, which lie on the surface and are usually easier to treat, and skull base meningiomas, which occur in deeper, anatomically complex regions. ‘If skull base meningiomas require surgery, the procedures are often more challenging because the tumours are in close proximity to important blood vessels and nerves,’ he adds, and continues:

“Many people have a meningioma without ever realising it, and it often remains undetected for their entire lives. Symptoms only arise when the tumour presses on specific structures – and the symptoms that occur depend heavily on its location. Headaches are common, usually caused by increased pressure within the skull. If the tumour is near the motor area, weakness in the arm or leg may occur; if it is near a speech centre, speech disorders are possible, and if it is in the occipital region, visual disturbances may occur. Some changes are more subtle, such as problems concentrating, slight changes in personality or increasing unsteadiness when walking. It is not just the size of the tumour that matters: a small meningioma in a critical location, such as at the base of the skull, can cause significantly more symptoms than a larger tumour in a less sensitive region. For this reason, three aspects are always considered together when making an assessment – imaging, progression over time and the patient’s actual condition.”

The WHO grade (WHO = World Health Organisation) plays a central role in determining the next course of action. WHO Grade I meningiomas are benign and have a very good prognosis, whilst Grade II and III tumours carry a higher risk of recurrence and require more frequent follow-up or additional treatments.

Prof. Dr. Stavrinou explains: “The ‘watch-and-wait’ approach only works under clear conditions: a meningioma must not be too large at the time of discovery, it must not cause any symptoms, and it must not show any growth over time. As long as these conditions are met, the patient can be monitored over a period of years, usually initially with annual MRI scans, and later at longer intervals. How long such monitoring is advisable also depends on the patient’s age. In older people, monitoring is not continued indefinitely, as intervention at a later stage would often no longer be a realistic option. Overall, however, a meningioma should be monitored for at least ten years if a ‘watch-and-wait’ approach is chosen. The question of when treatment becomes necessary cannot be determined by size alone. The decisive factor is whether any of the three criteria are met: if symptoms develop, if the tumour grows, or if its location is so unfavourable from the outset that a ‘watch-and-wait’ approach would be risky, observation is discontinued and treatment becomes necessary. The WHO grade describes how aggressive a meningioma is biologically. The most common tumours are classified as WHO grade 1; they grow slowly and are benign. WHO grade 2 tumours – the atypical meningiomas – have a higher risk of recurring after treatment. A WHO grade 3 tumour is rare, but significantly more aggressive and tends to experience renewed growth spurts despite treatment. We now know that microscopic assessment alone is not sufficient: molecular changes provide additional clues as to how a tumour might behave in the future. This information influences whether further treatment is necessary after surgery and how closely follow-up care should be monitored.”

Prof. Dr. med. Pantelis Stavrinou


Complete removal of a meningioma significantly reduces the risk of recurrence. However, in areas that are difficult to access or in the case of higher-grade meningiomas, this is not always possible – in such cases, radiotherapy supplements or replaces surgery. It is important to clarify before the procedure how high the neurological risk is, how realistic a complete resection appears to be, and how experienced the centre is with complex meningiomas.


Watchful waiting is always justified if a meningioma causes no symptoms, is small and shows no or only very slight growth on MRI. Many of these tumours grow extremely slowly or remain stable for years.

“For benign, non-space-occupying meningiomas, the frequency of follow-up scans is based on the recommendations of the European Society for Neuro-Oncology. Following the initial diagnosis, an MRI scan is carried out after six months, then after one year, and subsequently annually for around five years. If the tumour remains stable during this period, the intervals between check-ups can be gradually extended, for example to two or three years. After around ten years, a decision is made – depending on the patient’s age and overall situation – as to whether further check-ups are still necessary at all,” says Prof. Dr. Stavrinou.


The WHO grade indicates how ‘benign’ or ‘malignant’ a meningioma is from a biological perspective and thus determines the prognosis, risk of recurrence and follow-up care. Pathologists classify the tumour according to its grade based on cell division rate, tissue structure and invasive behaviour. From this, it is possible to deduce how likely it is that the tumour will grow again or grow more rapidly.


When deciding between surgery and radiotherapy, the first factor to consider is that surgical removal remains the most common and often the most effective treatment, as complete resection significantly reduces the risk of the tumour growing back. However, complete removal is not always advisable or safe.

“Radiotherapy is particularly suitable when the tumour is small and surgery would pose an increased risk due to its location, the patient’s general state of health or their age. In such situations, radiotherapy can be an equivalent or even better option. The two approaches are often combined, for example in the case of complex skull base meningiomas: the easily accessible part is removed surgically, whilst a small residual portion near critical structures such as major blood vessels or cranial nerves is targeted with radiotherapy. The question is therefore not so much whether to choose surgery or radiotherapy, but rather which combination offers the best balance between tumour control, safety and risk. It is entirely possible that radiotherapy will follow surgery. In the case of higher WHO-grade meningiomas, particularly Grade 2 and Grade 3, the risk of recurrence is significantly increased, so radiotherapy is planned shortly after surgery. Even with benign meningiomas, radiotherapy may become necessary at a later stage if a small, slowly growing recurrence develops over time. In such cases, repeat surgery is often not required, as radiotherapy can reliably control small recurrences. In the case of malignant WHO Grade 3 meningiomas, curative treatment may be possible under certain conditions. For this to be the case, the tumour must be completely removed, including its ‘root’ in the meninges, ideally with a safety margin. If radiotherapy is then administered as an additional treatment, there is a chance of a cure, although this is not guaranteed. Due to the aggressive nature of these tumours, close monitoring is necessary, usually every six months. ‘Even after complete removal and appropriate treatment, a recurrence may occur, which reflects the particular challenge posed by this type of tumour,’ explains Prof. Dr. Stavrinou.

Prof. Dr. med. Pantelis Stavrinou

Meningiomas and gliomas differ fundamentally in their aetiology, biological behaviour and therapeutic requirements. Meningiomas originate in the meninges and are usually located outside the actual brain tissue. They grow by displacement, often slowly, and push against the brain without infiltrating it. Gliomas, on the other hand, arise within the brain itself from glial cells – the supporting cells of the nervous system. They grow not only by displacement but also by infiltration; that is, they penetrate healthy brain tissue and spread along functional networks. This difference is crucial in terms of aetiology: whilst meningiomas are often benign and are clearly demarcated from the surrounding tissue, gliomas – particularly high-grade ones – are biologically more active, more difficult to control and often cannot be completely removed.

“Gliomas differ fundamentally from meningiomas because they do not originate from the meninges, but directly from the cells of the brain. As a result, they grow within the brain tissue itself and usually have no clear boundary. Individual tumour cells can extend far beyond what is visible on an MRI scan or detected during surgery. This makes the surgical situation considerably more complex: the aim is to remove as much of the tumour as possible without compromising important functions such as speech or movement. This balance between maximum tumour removal and functional safety is the central principle of modern glioma surgery. The symptoms caused by a glioma – as with meningiomas – depend heavily on its location and size. Here too, headaches, gradually increasing weakness, speech disorders or epileptic seizures may occur. The symptoms often develop somewhat more rapidly, but are essentially similar. However, a purely anatomical MRI scan is not sufficient for planning an operation. It is crucial to understand which functions are situated around the tumour and how closely it is linked to important neural networks. To this end, functional imaging, tractography and intraoperative neuromonitoring are used to make the operation as safe as possible,” explains Prof. Dr. Stavrinou.

The extent of resection is so important in gliomas because, unlike meningiomas, these tumours do not simply grow by displacement but infiltrate the brain tissue at a microscopic level. A glioma never consists solely of the visible tumour mass visible on an MRI scan. It spreads along nerve pathways, vascular structures and functional networks – often extending far beyond the radiologically detectable boundary. As a result, tumour tissue inevitably remains after every operation. The amount that remains has a direct impact on the subsequent course of the disease.

Prof. Dr. Stavrinou explains: “The difference between a radical and a precise operation today lies not simply in removing ‘more’ of the tumour, but in determining the boundary between the tumour and vital functions with ever-greater precision. To achieve this, several techniques are combined, each providing different information. Neuronavigation shows the anatomical location; 5-ALA fluorescence makes parts of the tumour visible that would be barely detectable under normal light; and intraoperative ultrasound shows, during the procedure, how much tumour remains. Neuromonitoring and direct electrical stimulation also enable the identification of functional structures that must be preserved at all costs. It is only the combination of these methods that makes it possible to remove as much of the tumour as possible without jeopardising neurological functions’, and he then explains what a wakeful craniotomy involves:

“A awake craniotomy is used when a tumour is located very close to regions of the brain whose function cannot be reliably tested whilst the patient is asleep. These include speech, complex motor functions, higher cognitive functions or the ability to speak multiple languages. During certain phases of the operation, the patient is awake, communicates with the team and carries out tasks that have been practised together beforehand. Depending on their hobbies or profession, some patients even play the violin or piano during the procedure, or switch between different languages, in order to test precisely these functions and abilities. During the operation, small areas of the brain are electrically stimulated. The patient identifies images, counts, reads or carries out complex tasks. If a function is temporarily disrupted by the stimulation, this indicates that this structure must be spared. This allows us to determine precisely which areas are functionally important and where surgery can be performed safely. Many people initially find the idea frightening. However, the brain tissue itself is not sensitive to pain, and the anaesthesia ensures that the patient remains awake but calm and pain-free. Preparation is crucial: the patient familiarises themselves with the operating theatre, sees the equipment, knows where they will be lying, and meets all the specialists involved. The tests that will later be carried out in the operating theatre are practised once or twice beforehand to rule out incorrect responses. During the procedure, the neuropsychologist communicates continuously with the patient whilst the surgeon operates. This structured approach allows for particularly precise work in functionally important regions of the brain: ‘removing more of the tumour without compromising neurological functions’.


5‑ALA makes parts of the tumour visible that remain invisible under white light. 5‑ALA is the abbreviation for 5‑aminolevulinic acid, an endogenous precursor of haem synthesis. After ingestion, tumour cells accumulate protoporphyrin IX and fluoresce pink–violet under blue light, whilst healthy tissue remains dark. This enables the surgeon to identify not only the visible tumour mass but also infiltrated areas and microscopic satellite foci that are only hinted at on MRI scans. The fluorescent areas mark biologically active tumour regions with a higher risk of recurrence. This allows the transition zone between the tumour and the brain to be precisely defined, enabling more of the tumour to be removed without crossing functional boundaries. This improves the quality of resection and reduces the tumour burden for subsequent treatment.


Intraoperative ultrasound, neuronavigation and neuromonitoring are three distinct yet closely interlinked tools which, during surgery, ensure that the procedure is more radical, more precise and, at the same time, safer. They complement one another because each of these techniques provides a different type of information: spatial orientation, real-time imaging and functional feedback. Together, they enable maximum safe resection – that is, the greatest possible removal of tumour tissue without causing additional neurological deficits.

“Modern techniques in brain tumour surgery do not aim to operate ‘more aggressively’, but rather with greater precision. To achieve this, several techniques are combined, each providing different types of information: neuronavigation shows the anatomical position, functions as a precise guidance system and links the pre-operative imaging data with the actual anatomy in the operating theatre. 5-ALA fluorescence makes certain parts of the tumour visible, whilst intraoperative ultrasound uses real-time images during the procedure to show how much of the tumour remains. Neuromonitoring and direct electrical stimulation, meanwhile, identify functionally important structures. Where is a critical function that requires caution or a halt to the procedure? Together, these techniques make it possible to precisely determine the boundary between the tumour and healthy, functionally relevant tissue – and thus to remove more of the tumour without jeopardising neurological functions,” explains Prof. Dr. Stavrinou.

Prof. Dr. med. Pantelis Stavrinou

Following a successful operation, the length of stay in hospital depends on how well the patient recovers neurologically. As a rule, both meningioma and glioma patients remain in hospital for around three to four days. Within the first 24 hours, a new imaging scan – CT or MRI – is carried out to assess the outcome of the operation. If the results look good, the patient is stable and able to move around, there is nothing to prevent them from being discharged home.

Prof. Dr. Stavrinou comments: “The subsequent follow-up care differs significantly between meningiomas and gliomas. Gliomas are not benign tumours, which is why combined radiotherapy and chemotherapy is necessary after surgery. This begins around 20 to 30 days after the procedure. The patient receives a total of around 30 radiotherapy sessions over six weeks, from Monday to Friday, followed by six cycles of chemotherapy in tablet form. The likelihood of a recurrence depends heavily on the type of tumour. High-grade gliomas in particular – glioblastomas and anaplastic gliomas – almost invariably tend to recur. Recurrence is the rule rather than the exception. Despite the aggressive nature of these tumours, the prognosis has improved in recent years: new drugs and modern treatment approaches now not only enable longer survival times but also a significantly better quality of life, which is of great importance to many patients.”


“Artificial intelligence already plays an important role today – though primarily in diagnostics. With the help of AI, imaging techniques such as MRI or CT can be analysed so precisely that the models sometimes provide findings that are just as accurate, and sometimes even more accurate, than those of a radiologist. AI is not yet used during the operation itself, but this is precisely where it will next become established: in the processing of anatomical and functional data from neuronavigation and neuromonitoring. In future, pre-operative information could be generated automatically, and AI could calculate in real time how likely it is that an important function is located at a specific site. The first AI-assisted procedures – for example, for pituitary adenomas – have already been carried out. “Development is progressing rapidly and will bring about a noticeable change in intraoperative decision-making,” says Prof. Dr. Stavrinou.


Patients can recognise a truly highly specialised centre by the fact that modern techniques such as neuronavigation, intraoperative ultrasound and neuromonitoring are not only available but are actually used routinely and to a high standard. This is evident not from marketing claims, but from clear, verifiable characteristics in day-to-day clinical practice and in the way the team discusses the procedure.

“A patient seeking the right neurosurgical treatment should focus less on individual pieces of equipment or technical buzzwords, and more on whether a centre routinely and sensibly integrates these techniques into an overall treatment plan. It is crucial that modern neuro-oncology always operates on an interdisciplinary basis: neuroradiology, neuropathology, neuro-oncology, radiotherapy and neurosurgery must work closely together and coordinate their decisions within a tumour board. It is equally important that technologies such as navigation, fluorescence or neuromonitoring are not used as an end in themselves, but in a targeted manner appropriate to the specific tumour. True expertise lies in selecting the right tools for each individual case and combining them in such a way that tumour control and functional safety are optimally balanced. For patients, a simple question is often particularly revealing: ‘How exactly are you planning my operation to remove as much of the tumour as possible whilst protecting my functions?’ The quality of the answer usually says more than long lists of technical equipment or mere case numbers. The relationship between doctor and patient also plays a major role. Particularly with brain tumours, trust, clear communication and the feeling of being well looked after are essential. “A centre that carries out many such procedures not only has the necessary experience but also the structures that are indispensable for complex treatment,” emphasises Prof. Dr. Stavrinou at the end of our conversation.


  • Experienced neurosurgeon with many years of clinical practice in leading European university hospitals
  • Senior Registrar in Neurosurgery at Cologne from 2011–2019; Director of Neurosurgery at the Metropolitan Hospital Athens since 2020
  • Habilitation and appointment as a Privatdozent at the University of Cologne, 2020
  • Professor of Neurosurgery at the University of Nicosia, 2025
  • Specialist in neuro-oncology, skull base surgery and minimally invasive spinal surgery
  • High level of surgical expertise: numerous complex brain tumour and spinal surgeries; internationally sought-after course leader
  • Director of the ‘Cologne Skull Base Course’ for many years; training neurosurgeons from all over the world
  • Co-author of official EANO guidelines on meningiomas (2016, 2021) and vestibular schwannomas (Neuro-Oncology 2020;22(1):31–45)
  • Participation in international neuro-oncology studies; numerous publications in leading specialist journals
  • Master’s diploma from the German Spine Society, specialising in microdiscectomy, percutaneous fusion, kyphoplasty and XLIF
  • International training: placements in Cologne, Hanover, Munich (paediatric neurosurgery), Thessaloniki and Athens, amongst others
  • Recipient of multiple awards: research prizes in 2009 and 2017, and an Honourable Mention in the EANS Research Prize 2018

Share this article

Alexandra_Pfitzmann.jpg

About the medical author

Alexandra Pfitzmann

Editor

More about the medical author →

Expert Interviews

Read next

Portrait of Prof. Pantelis Stavrinou, MD, PhD

Prof. Pantelis Stavrinou, MD, PhD

Athens